Heterocyclic compounds as adenosine antagonists

1. A compound of the formula (I):

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

A is 4-hydroxyphenyl optionally further substituted by R 3 , 4-hydroxy-2-pyridyl optionally further substituted by R 4 , a naphthyl substituted by R 4 , a 9- or 10-membered bicyclic heterocyclyl optionally substituted by R 4 , or a 10-membered bicyclic heteroaryl optionally substituted by R 4 ;

B is a phenyl optionally substituted by R 3 , C 3 -C 6 cycloalkyl optionally substituted by R 4 , 3- to 6-membered heterocyclyl optionally substituted by R 4 or a 5- to 10-membered heteroaryl optionally substituted by R 4 ;

R 1 is a hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-6-membered heterocyclyl), —(C 1 -C 3 alkylene)(5-6-membered heteroaryl), —(C 1 -C 3 alkylene)(C 6 aryl), —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , —NR 1b R 1c , —S(O) 2 R 1a , —(C 1 -C 3 alkylene)C(O)NR 1b R 1c , —(C 1 -C 3 alkylene)C(O)R 1a or —(C 1 -C 3 alkylene)NR 1b R 1c , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, 5- to 10-membered heteroaryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-6-membered heterocyclyl), —(C 1 -C 3 alkylene)(5-6-membered heteroaryl), and —(C 1 -C 3 alkylene)(C 6 aryl) of R 1 are independently optionally substituted by R4;

each R 1a is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, 3-6-membered heterocyclyl, C 6 aryl, 5-6-membered heteroaryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-6-membered heterocyclyl), —(C 1 -C 3 alkylene)(C 6 aryl) or —(C 1 -C 3 alkylene)(5-6-membered heteroaryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF 3 , —OH, —OCH 3 , —CN, —C(O)OCH 3 , —C(O)OC 2 H 5 , —NH 2 or —NHCH 3 ;

each R 1b and R 1c is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, 3-6-membered heterocyclyl, C 6 aryl, 5-6-membered heteroaryl, —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-6-membered heterocyclyl), —(C 1 -C 3 alkylene)(C 6 aryl) or —(C 1 -C 3 alkylene)(5-6-membered heteroaryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF 3 , —OH, —OCH 3 , —CN, —C(O)OCH 3 , —C(O)OC 2 H 5 , —NH 2 or —NHCH 3 ;

or R 1b and R 1c are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclyl;

R 2 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 14 aryl, C 5 -C 14 heteroaryl, C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, —CN, halogen, —OR 2 a, —SR 2a , —NR 2b R 2c , —C(O)R 2a , —NR 2b C(O)R 2c , —NR 2a C(O)NR 2b R 2c , —C(O)OR 2a , —C(O)ONR 2b R 2c or —C(O)NR 2b R 2c , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 14 aryl, C 3 -C 6 cycloalkyl and 3- to 6-membered heterocyclyl of R 2 are independently optionally substituted by R 4 ;

each R 2a is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6 -aryl, 5- to 6-membered heteroaryl, —(C 1 -C 3 alkylene)N(C 2 H 5 ) 2 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-6-membered heterocyclyl), —(C 1 -C 3 alkylene)(5-6-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 aryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF 3 , —OH, —OCH 3 , —CN, —C(O)OCH 3 , —C(O)OC 2 H 5 , —NH 2 or —NHCH 3 ;

each R 2b and R 2c is independently hydrogen, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, C 6 -aryl, 5- to 6-membered heteroaryl, —(C 1 -C 3 alkylene)N(C 2 H 5 ) 2 , —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-6-membered heterocyclyl), —(C 1 -C 3 alkylene)(C 6 aryl) or —(C 1 -C 3 alkylene)(5-6-membered heteroaryl), wherein each of which is optionally substituted by methyl, ethyl, halogen, oxo, —CF 3 , —OH, —OCH 3 , —CN, —C(O)OCH 3 , —C(O)OC 2 H 5 , —NH 2 or —NHCH 3 ;

or R 2b and R 2′ are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclyl;

each R 3 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, —CN, —OR 5 , —SR 5 , —NR 6 R 7 , —NO 2 , —C═NH(OR 5 ), —C(O)R 5 , —OC(O)R 5 , —C(O)OR 5 , —C(O)NR 6 R 7 , —OC(O)NR 6 R 7 , —NR 5 C(O)R 6 , —NR 5 C(O)OR 6 , —NR 5 C(O)NR 6 R 7 , —S(O)R 5 , —S(O) 2 R 5 , —NR 5 S(O)R 6 , —C(O)NR 5 S(O)R 6 , —NR 5 S(O) 2 R 6 , —C(O)NR 5 S(O) 2 R 6 , —S(O)NR 6 R 7 , —S(O) 2 NR 6 R 7 , —P(O)(OR 6 ) (OR 7 ), C 3 -C 6 cycloalkyl, 3-12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 5 , —(C 1 -C 3 alkylene)SR 5 , —(C 1 -C 3 alkylene)NR 6 R 7 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)NO 2 , —C═NH(OR 5 ), —(C 1 -C 3 alkylene)C(O)R 5 , —(C 1 -C 3 alkylene)OC(O)R 5 , —(C 1 -C 3 alkylene)C(O)OR 5 , —(C 1 -C 3 alkylene)C(O)NR 6 R 7 , —(C 1 -C 3 alkylene)OC(O)NR 6 R 7 , —(C 1 -C 3 alkylene)NR 5 C(O)R 6 , —(C 1 -C 3 alkylene)NR 5 C(O)OR 6 , —(C 1 -C 3 alkylene)NR 5 C(O)NR 6 R 7 , —(C 1 -C 3 alkylene)S(O)R 5 , —(C 1 -C 3 alkylene)S(O) 2 R 5 , —(C 1 -C 3 alkylene)NR 5 S(O)R 6 , —C(O)(C 1 -C 3 alkylene)NR 5 S(O)R 6 , —(C 1 -C 3 alkylene)NR 5 S(O) 2 R 6 , —(C 1 -C 3 alkylene)C(O)NR 5 S(O) 2 R 6 , —(C 1 -C 3 alkylene)S(O)NR 6 R 7 , —(C 1 -C 3 alkylene)S(O) 2 NR 6 R 7 , —(C 1 -C 3 alkylene)P(O)(OR 6 )(OR 7 ), —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5-10-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein each R 3 is independently optionally substituted by halogen, oxo, —OR 8 , —NR 8 R 9 , —C(O)R 8 , —CN, —S(O)R 8 , —S(O) 2 R 8 , —P(O)(OR 8 )(OR 9 ), —(C 1 -C 3 alkylene)OR 8 , —(C 1 -C 3 alkylene)NR 8 R 9 , —(C 1 -C 3 alkylene)C(O)R 8 , —(C 1 -C 3 alkylene)S(O)R 8 , —(C 1 -C 3 alkylene)S(O) 2 R 8 , —(C 1 -C 3 alkylene)P(O)(OR 8 )(OR 9 ), C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen;

each R 4 is independently oxo or R 3 ;

R 5 is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl or 3-6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl and 3-6-membered heterocyclyl of R 5 are independently optionally substituted by halogen, oxo, —CN, —OR 9 , —NR 9 R 10 , —P(O)(OR 9 )(OR 10 ), phenyl optionally substituted by halogen, or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

R 6 and R 7 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl, —(C 1 -C 3 alkylene)(C 6 aryl) or 3-6 membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl, —(C 1 -C 3 alkylene)(C 6 aryl) and 3-6 membered heterocyclyl of R 6 and R 7 are independently optionally substituted by halogen, oxo, —CN, —OR 9 , —NR 9 R 10 or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

or R 6 and R 7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo, —OR 9 , —NR 9 R 10 or C 1 -C 6 alkyl optionally substituted by halogen, oxo or —OH;

R 8 and R 9 in R 3 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo;

or R 8 and R 9 in R 3 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by halogen or oxo; and

R 9 and R 10 in R 5 , R 6 and R 7 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo;

or R 9 and R 10 in R 5 , R 6 and R 7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by oxo or halogen.

2. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

A is 4-hydroxyphenyl optionally further substituted by R 3 , 4-hydroxy-2-pyridyl optionally further substituted by R 4 , or a 10-membered bicyclic heteroaryl optionally substituted by R 4 ;

B is a phenyl optionally substituted by R 3 , or 5- to 6-membered heteroaryl optionally substituted by R 4 ;

R 1 is a hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, 3- to 6-membered heterocyclyl, —C(O)R 1a , —C(O)OR 1a , —C(O)NR 1b R 1c , or —NR 1b R 1c , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl and 3- to 6-membered heterocyclyl of R 1 are independently optionally substituted by R 4 ;

each R 1a is independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 1b and R 1c is independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

or R 1b and R 1c are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclyl;

R 2 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 6 -C 14 aryl, —CN, halogen, —OR 2 a, —NR 2b R 2 ″, —C(O)R 2 a, —C(O)OR 2 a, or —C(O)NR 2b R 2′ , wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl and C 6 -C 14 aryl of R 2 are independently optionally substituted by R 4 ;

each R 2a is independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

each R 2b and R 2c is independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

or R 2b and R 2c are taken together with the nitrogen atom to which they are attached to form a 3- to 6-membered heterocyclyl;

each R 3 is independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, halogen, —CN, —OR 5 , —SR 5 , —NR 6 R 7 , —NO 2 , —C═NH(OR 5 ), —C(O)R 5 , —OC(O)R 5 , —C(O)OR 5 , —C(O)NR 6 R 7 , —OC(O)NR 6 R 7 , —NR 5 C(O)R 6 , —NR 5 C(O)OR 6 , —NR 5 C(O)NR 6 R 7 , —S(O)R 5 , —S(O) 2 R 5 , —NR 5 S(O)R 6 , —C(O)NR 5 S(O)R 6 , —NR 5 S(O) 2 R 6 , —C(O)NR 5 S(O) 2 R 6 , —S(O)NR 6 R 7 , —S(O) 2 NR 6 R 7 , —P(O)(OR 6 ) (OR 7 ), C 3 -C 6 cycloalkyl, 3-12-membered heterocyclyl, 5- to 10-membered heteroaryl, C 6 -C 14 aryl, —(C 1 -C 3 alkylene)CN, —(C 1 -C 3 alkylene)OR 5 , —(C 1 -C 3 alkylene)SR 5 , —(C 1 -C 3 alkylene)NR 6 R 7 , —(C 1 -C 3 alkylene)CF 3 , —(C 1 -C 3 alkylene)NO 2 , —C═NH(OR 5 ), —(C 1 -C 3 alkylene)C(O)R 5 , —(C 1 -C 3 alkylene)OC(O)R 5 , —(C 1 -C 3 alkylene)C(O)OR 5 , —(C 1 -C 3 alkylene)C(O)NR 6 R 7 , —(C 1 -C 3 alkylene)OC(O)NR 6 R 7 , —(C 1 -C 3 alkylene)NR 5 C(O)R 6 , —(C 1 -C 3 alkylene)NR 5 C(O)OR 6 , —(C 1 -C 3 alkylene)NR 5 C(O)NR 6 R 7 , —(C 1 -C 3 alkylene)S(O)R 5 , —(C 1 -C 3 alkylene)S(O) 2 R 5 , —(C 1 -C 3 alkylene)NR 5 S(O)R 6 , —C(O)(C 1 -C 3 alkylene)NR 5 S(O)R 6 , —(C 1 -C 3 alkylene)NR 5 S(O) 2 R 6 , —(C 1 -C 3 alkylene)C(O)NR 5 S(O) 2 R 6 , —(C 1 -C 3 alkylene)S(O)NR 6 R 7 , —(C 1 -C 3 alkylene)S(O) 2 NR 6 R 7 , —(C 1 -C 3 alkylene)P(O)(OR 6 )(OR 7 ), —(C 1 -C 3 alkylene)(C 3 -C 6 cycloalkyl), —(C 1 -C 3 alkylene)(3-12-membered heterocyclyl), —(C 1 -C 3 alkylene)(5-10-membered heteroaryl) or —(C 1 -C 3 alkylene)(C 6 -C 14 aryl), wherein each R 3 is independently optionally substituted by halogen, oxo, —OR 8 , —NR 8 R 9 , —C(O)R 8 , —CN, —S(O)R 8 , —S(O) 2 R 8 , —P(O)(OR 8 )(OR 9 ), —(C 1 -C 3 alkylene)OR 8 , —(C 1 -C 3 alkylene)NR 8 R 9 , —(C 1 -C 3 alkylene)C(O)R 8 , —(C 1 -C 3 alkylene)S(O)R 8 , —(C 1 -C 3 alkylene)S(O) 2 R 8 , —(C 1 -C 3 alkylene)P(O)(OR 8 )(OR 9 ), C 3 -C 8 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by oxo, —OH or halogen;

each R 4 is independently oxo or R 3 ;

R 5 is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl or 3-6-membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl and 3-6-membered heterocyclyl of R 5 are independently optionally substituted by halogen, oxo, —CN, —OR 9 , —NR 9 R 10 , —P(O)(OR 9 )(OR 10 ), phenyl optionally substituted by halogen, or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

R 6 and R 7 are each independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl or 3-6 membered heterocyclyl, wherein the C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 6 cycloalkyl, C 6 -C 14 aryl, 5-6-membered heteroaryl and 3-6 membered heterocyclyl of R 6 and R 7 are independently optionally substituted by halogen, oxo, —CN, —OR 9 , —NR 9 R 10 or C 1 -C 6 alkyl optionally substituted by halogen, —OH or oxo;

or R 6 and R 7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo, —OR 9 , —NR 9 R 10 or C 1 -C 6 alkyl optionally substituted by halogen, oxo or —OH;

R 8 and R 9 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo;

or R 8 and R 9 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by halogen or oxo; and

R 9 and R 10 are each independently hydrogen, C 1 -C 6 alkyl optionally substituted by halogen or oxo, C 2 -C 6 alkenyl optionally substituted by halogen or oxo, or C 2 -C 6 alkynyl optionally substituted by halogen or oxo;

or R 9 and R 10 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl optionally substituted by halogen, oxo or C 1 -C 6 alkyl optionally substituted by oxo or halogen.

3. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is hydrogen or —C(O)R 1a .

4. The compound of claim 3 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is hydrogen.

5. The compound of claim 3 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 is —C(O)R 1a and R 1a is C 1 -C 6 alkyl.

6. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is hydrogen, C 1 -C 6 alkyl, —CN, halogen, —OR 2a .

7. The compound of claim 6 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is hydrogen.

8. The compound of claim 6 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is C 1 -C 6 alkyl.

9. The compound of claim 6 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is CN or halogen.

10. The compound of claim 6 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 2 is —OR 2a and R 2a is C 1 -C 6 alkyl.

11. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is 4-hydroxyphenyl optionally further substituted by R 3 or 4-hydroxy-2-pyridyl optionally further substituted by R 4 .

12. The compound of claim 11 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is 4-hydroxyphenyl optionally further substituted by R 3 .

13. The compound of claim 11 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is 4-hydroxy-2-pyridyl optionally further substituted by R 4 .

14. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is a 10-membered bicyclic heteroaryl optionally substituted by R 4 .

15. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the A is selected from the group consisting of quinolinyl, isoquinolinyl, quinoxalinyl, quinazolinyl, cinnolinyl, and naphthyridinyl, each of which is optionally substituted by R 4 .

16. The compound of claim 15 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is R 3 and each R 3 is independently selected from the group consisting of halogen, —CN, —OR 5 , —SR 5 , —NR 6 R 7 , —NO 2 , —C(O)R 5 , —C(O)OR 5 , —C(O)NR 6 R 7 , —C(O)NR 5 S(O) 2 R 6 , —OC(O)R 5 , —OC(O)NR 6 R 7 , —NR 5 C(O)R 6 , —NR 5 C(O)NR 6 R 7 , —S(O)R 5 , —S(O) 2 R 5 , C 3 -C 6 cycloalkyl and C 1 -C 6 alkyl optionally substituted by halogen.

17. The compound of claim 16 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each R 3 is independently selected from the group consisting of halogen, —OR 5 and C 1 -C 6 alkyl optionally substituted by halogen.

18. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is selected from the group consisting of:

19. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is selected from the group consisting of:

20. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein B is a phenyl optionally substituted by R 3 .

21. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein B is a 5- to 6-membered heteroaryl optionally substituted by R 4 .

22. The compound of claim 21 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the B is a 5-membered heteroaryl selected from the group consisting of furanyl, oxazolyl, thiophenyl, pyrazolyl, isoxazolyl, 1,3,4-oxadiazolyl, imidazolyl, thiazolyl, isothiazolyl, triazolyl, 1,3,4-thiadiazolyl and tetrazolyl, which is optionally substituted by R 4 .

23. The compound of claim 21 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the B is a 6-membered heteroaryl selected from the group consisting of pyridyl and pyrimidinyl, which is optionally substituted by R 4 .

24. The compound of claim 21 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is R 3 and R 3 is selected from the group consisting of halogen, —OR 5 , —NR 6 R 7 , —C(O)R 5 , C 3 -C 6 cycloalkyl and C 1 -C 6 alkyl optionally substituted by halogen.

25. The compound of claim 24 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is selected from the group consisting of halogen and C 1 -C 6 alkyl optionally substituted by halogen.

26. The compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein B is selected from the group consisting of:

27. The compound of claim 1 , wherein the compound is of the formula (II):

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 , R 2 and B are as defined for formula (I);

X is N or CH;

each R 3 is independently halogen, —CN, —OR 5 , —SR 5 , —NR 6 R 7 , —NO 2 , —C(O)R 5 , —C(O)OR 5 , —C(O)NR 6 R 7 , —C(O)NR 5 S(O) 2 R 6 , —OC(O)R 5 , —OC(O)NR 6 R 7 , —NR 5 C(O)R 6 , —NR 5 C(O)NR 6 R 7 , —S(O)R 5 , —S(O) 2 R 5 , C 3 -C 6 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by halogen;

each R 5 is independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

R 6 and R 7 are each independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

or R 6 and R 7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl; and

n is 0, 1, 2 or 3.

28. The compound of claim 27 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 3 is selected from the group consisting of halogen, —OR 5 and C 1 -C 6 alkyl optionally substituted by halogen.

29. The compound of claim 1 , wherein the compound is of the formula (IVc):

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 1 , R 2 and B are as defined for formula (I);

each X 3 is independently CR 4 , CH or N;

each R 4 is independently halogen, —CN, —OR 5 , —SR 5 , —NR 6 R 7 , —NO 2 , —C(O)R 5 , —C(O)OR 5 , —C(O)NR 6 R 7 , —C(O)NR 5 S(O) 2 R 6 , —OC(O)R 5 , —OC(O)NR 6 R 7 , —NR 5 C(O)R 6 , —NR 5 C(O)NR 6 R 7 , —S(O)R 5 , —S(O) 2 R 5 , C 3 -C 6 cycloalkyl, or C 1 -C 6 alkyl optionally substituted by halogen;

where each R 5 is independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl; and

R 6 and R 7 are each independently hydrogen, C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl;

or R 6 and R 7 are taken together with the atom to which they attached to form a 3-6 membered heterocyclyl.

30. The compound of claim 29 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R 4 is selected from the group consisting of halogen, —OR 5 and C 1 -C 6 alkyl optionally substituted by halogen.

31. The compound of claim 29 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X 3 is N, and the remaining X 3 are each CR 4 .

32. The compound of claim 29 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein two of X 3 are N, and the remaining X 3 are each CR 4 .

33. A compound selected from the group consisting of

or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

34. The compound of claim 33 , or a pharmaceutically acceptable salt thereof.

35. A pharmaceutical composition comprising a compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier.

36. A method of treating disease mediated by an adenosine signaling pathway in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

37. A method of treating cancer in an individual in need thereof comprising administering to the individual a therapeutically effective amount of a compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

38. A method of inhibiting an adenosine receptor of subtype A2A, A2B or A3 in a cell, comprising administering a compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to the cell.

39. The method of claim 38 , wherein the adenosine receptor is of subtype A2A.

40. A kit comprising a compound of claim 1 , or a tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

41. The compound of claim 33 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

42. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

43. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

44. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

45. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

46. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

47. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

48. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

49. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

50. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

51. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is

52. The compound of claim 41 , or a pharmaceutically acceptable salt thereof, wherein the compound is